Cholesterol and APOE genotype interact to influence Alzheimer disease progression.
In this retrospective analysis of 443 Alzheimer disease (AD) patients from a 30-week tacrine trial, change in Alzheimer's Disease Assessment Scale score from baseline to final value was significantly associated with a total serum cholesterol/APOE genotype interaction. Disease progression in the no-APOE epsilon4 allele/high-cholesterol subgroup was greater than in the normal-cholesterol subgroups with or without epsilon4. Cholesterol levels and APOE genotype may interact to affect AD progression. The results are consistent with preclinical data on cholesterol's effects in AD.
Evans
R M
RM
Department of Neurology, Indiana University School of Medicine, Indianapolis, USA. revans1@iupui.edu
Hui
S
S
Perkins
A
A
Lahiri
D K
DK
Poirier
J
J
Farlow
M R
MR
D000368:Aged; D000544:Alzheimer Disease / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000235:genetics*; D053327:Apolipoprotein E4; D001057:Apolipoproteins E / Q000235:genetics*; D002784:Cholesterol / Q000097:blood*; D018450:Disease Progression; D004311:Double-Blind Method; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000150:complications / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use; D012189:Retrospective Studies; D012720:Severity of Illness Index; D013619:Tacrine / Q000627:therapeutic use
D053327:Apolipoprotein E4; D001057:Apolipoproteins E; D018696:Neuroprotective Agents; D013619:Tacrine; D002784:Cholesterol